Redsense gets US nod for needle dislodgement alarm:
This article was originally published in Clinica
Swedish firm Redsense Medical has received 510(k) clearance from the US FDA for its alarm for venous needle dislodgement. The device, for use in haemodialysis patients, can detect as little as 1mm of blood that is released after dislodgement. The product, called Redsense, consists of two parts: a sensor patch and an alarm unit. In the event of bleeding, inner layers of the patch smear blood over the optical sensor, which triggers the alarm. Over 200 million dialysis treatments are performed every year, a number set to increase with the world's ageing population, claimed the Halmstad company. Serious incidents due to needle dislodgment during haemodialysis are estimated to be in the thousands, said Redsense.
You may also be interested in...
Amarin had argued that Vascepa’s sales success showed that its patents were not obvious, but the court found otherwise, even as it concluded that Hikma, Dr. Reddy's and West-Ward has infringed on the fish oil pill's patents.
Grail announced results from an initial validation study that showed its early-detection blood test could identify 12 of the deadliest cancers with a low rate of false-positive results.
Shanghai Henlius Biotech has announced that China’s NMPA has accepted the firm’s filing for its HLX14 denosumab biosimilar. Meanwhile, the company has also announced dosing the first patient in a Phase II clinical trial of its novel HLX10 anti-PD-1 monoclonal antibody.